肾癌是泌尿系肿瘤中居第二位的常见肿瘤,且发病率呈逐年上升趋势。一旦肾癌发生远处转移,其5年生存率不足20%。在肾癌发生、发展过程中,存在多种DNA甲基化异常,DNA甲基化成为除DNA突变和缺失外,导致抑癌基因失活的最重要机制之一。本文就近年来甲基化抑制药及在肾癌治疗中的应用进展综述如下。 Renal cancer is the second most common tumor in urological tumors, and the incidence is increasing year by year. Once the distant metastasis of renal cell carcinoma, the 5-year survival rate of less than 20%. In the occurrence and development of renal cell carcinoma, there exist a variety of DNA methylation abnormalities, and DNA methylation becomes one of the most important mechanisms leading to the inactivation of the tumor suppressor gene besides DNA mutations and deletions. In this paper, in recent years, methylation inhibitor and its application in the treatment of renal cell carcinoma are summarized as follows.